Recent Corporate Developments and Planned Later Stage Clinical Trials to Be Highlighted
NEW YORK, NY--(November 30, 2015) - Actinium Pharmaceuticals, Inc. (ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company announced today that it is schedule to present at the 8th Annual LD Micro Main Event being held December 1 - 3, 2015 at the Sunset Luxe in Los Angeles, CA.
Actinium's Executive Chairman, Sandesh Seth, M.S., MBA, is scheduled to present at 2:00 PM PST. In his presentation, Mr. Seth will highlight the Company's recent clinical developments and its planned pivotal, Phase 3 clinical trial for Iomab-B and Phase 2 clinical trial for Actimab-A, which will transform Actinium into a later stage targeted payload immunotherapeutic company.
"The LD Micro Main Event has grown significantly in recent years and has become a leading conference for emerging growth companies. Actinium is excited to be participating again this year and we look forward to providing the investment community with highlights of our exciting targeted payload immunotherapeutic programs, Iomab-B and Actimab-A, in our presentation and in one-on-one meetings," said Sandesh Seth, M.S., MBA, Executive Chairman of Actinium Pharmaceuticals.
Conference attendees and members of the investment community can obtain additional information or schedule one-on-one meetings by contacting Steve O'Loughlin via email email@example.com.
About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact (408) 457-1042 or visit www.ldmicro.com.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Senior Director, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer